Adicet Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACET Nasdaq 2836 www.adicetbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adicet Bio, Inc.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Nov 28th, 2025 12:23 pm
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance - Nov 12th, 2025 2:05 pm
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Nov 5th, 2025 2:01 pm
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Oct 31st, 2025 2:59 pm
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference - Oct 28th, 2025 5:00 am
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) - Oct 16th, 2025 5:00 am
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? - Oct 7th, 2025 7:40 am
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering - Oct 7th, 2025 5:01 am
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) - Oct 7th, 2025 4:45 am
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know - Sep 30th, 2025 10:00 am
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 5:00 am
Adicet Bio (ACET) Upgraded to Buy: Here's Why - Aug 12th, 2025 10:00 am
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Aug 11th, 2025 7:46 am
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Aug 7th, 2025 2:01 pm
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance - Aug 6th, 2025 2:05 pm
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference - Aug 5th, 2025 5:00 am
MaxCyte Signs Platform License Agreement with Adicet Bio - Aug 4th, 2025 6:05 am
Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 - Jul 25th, 2025 5:27 am
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Jul 24th, 2025 5:00 am
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference - May 21st, 2025 2:00 pm